Cargando…
A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2
Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 str...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Authors.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695190/ https://www.ncbi.nlm.nih.gov/pubmed/34990583 http://dx.doi.org/10.1016/j.celrep.2021.110256 |
| _version_ | 1784619519955697664 |
|---|---|
| author | Yuan, Yaochang Zhang, Xiantao Chen, Ran Li, Yuzhuang Wu, Bolin Li, Rong Zou, Fan Ma, Xiancai Wang, Xuemei Chen, Qier Deng, Jieyi Zhang, Yongli Chen, Tao Lin, Yingtong Yan, Shumei Zhang, Xu Li, Congrong Bu, Xiuqing Peng, Yi Ke, Changwen Deng, Kai Pan, Ting He, Xin Zhang, Yiwen Zhang, Hui |
| author_facet | Yuan, Yaochang Zhang, Xiantao Chen, Ran Li, Yuzhuang Wu, Bolin Li, Rong Zou, Fan Ma, Xiancai Wang, Xuemei Chen, Qier Deng, Jieyi Zhang, Yongli Chen, Tao Lin, Yingtong Yan, Shumei Zhang, Xu Li, Congrong Bu, Xiuqing Peng, Yi Ke, Changwen Deng, Kai Pan, Ting He, Xin Zhang, Yiwen Zhang, Hui |
| author_sort | Yuan, Yaochang |
| collection | PubMed |
| description | Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants. |
| format | Online Article Text |
| id | pubmed-8695190 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The Authors. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86951902021-12-23 A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 Yuan, Yaochang Zhang, Xiantao Chen, Ran Li, Yuzhuang Wu, Bolin Li, Rong Zou, Fan Ma, Xiancai Wang, Xuemei Chen, Qier Deng, Jieyi Zhang, Yongli Chen, Tao Lin, Yingtong Yan, Shumei Zhang, Xu Li, Congrong Bu, Xiuqing Peng, Yi Ke, Changwen Deng, Kai Pan, Ting He, Xin Zhang, Yiwen Zhang, Hui Cell Rep Report Inoculation against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is ongoing worldwide. However, the emergence of SARS-CoV-2 variants could cause immune evasion. We developed a bivalent nanoparticle vaccine that displays the receptor binding domains (RBDs) of the D614G and B.1.351 strains. With a prime-boost or a single-dose strategy, this vaccine elicits a robust neutralizing antibody and full protection against infection with the authentic D614G or B.1.351 strain in human angiotensin-converting enzyme 2 transgene mice. Interestingly, 8 months after inoculation with the D614G-specific vaccine, a new boost with this bivalent vaccine potently elicits cross-neutralizing antibodies for SARS-CoV-2 variants in rhesus macaques. We suggest that the D614G/B.1.351 bivalent vaccine could be used as an initial single dose or a sequential enforcement dose to prevent infection with SARS-CoV-2 and its variants. The Authors. 2022-01-18 2021-12-23 /pmc/articles/PMC8695190/ /pubmed/34990583 http://dx.doi.org/10.1016/j.celrep.2021.110256 Text en © 2021 The Authors Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Report Yuan, Yaochang Zhang, Xiantao Chen, Ran Li, Yuzhuang Wu, Bolin Li, Rong Zou, Fan Ma, Xiancai Wang, Xuemei Chen, Qier Deng, Jieyi Zhang, Yongli Chen, Tao Lin, Yingtong Yan, Shumei Zhang, Xu Li, Congrong Bu, Xiuqing Peng, Yi Ke, Changwen Deng, Kai Pan, Ting He, Xin Zhang, Yiwen Zhang, Hui A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 |
| title | A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 |
| title_full | A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 |
| title_fullStr | A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 |
| title_full_unstemmed | A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 |
| title_short | A bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of SARS-CoV-2 |
| title_sort | bivalent nanoparticle vaccine exhibits potent cross-protection against the variants of sars-cov-2 |
| topic | Report |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8695190/ https://www.ncbi.nlm.nih.gov/pubmed/34990583 http://dx.doi.org/10.1016/j.celrep.2021.110256 |
| work_keys_str_mv | AT yuanyaochang abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhangxiantao abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT chenran abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT liyuzhuang abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT wubolin abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT lirong abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zoufan abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT maxiancai abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT wangxuemei abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT chenqier abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT dengjieyi abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhangyongli abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT chentao abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT linyingtong abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT yanshumei abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhangxu abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT licongrong abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT buxiuqing abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT pengyi abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT kechangwen abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT dengkai abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT panting abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT hexin abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhangyiwen abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhanghui abivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT yuanyaochang bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhangxiantao bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT chenran bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT liyuzhuang bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT wubolin bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT lirong bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zoufan bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT maxiancai bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT wangxuemei bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT chenqier bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT dengjieyi bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhangyongli bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT chentao bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT linyingtong bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT yanshumei bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhangxu bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT licongrong bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT buxiuqing bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT pengyi bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT kechangwen bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT dengkai bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT panting bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT hexin bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhangyiwen bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 AT zhanghui bivalentnanoparticlevaccineexhibitspotentcrossprotectionagainstthevariantsofsarscov2 |